Afshin Dowlati

Afshin Dowlati

UNVERIFIED PROFILE

Are you Afshin Dowlati?   Register this Author

Register author
Afshin Dowlati

Afshin Dowlati

Publications by authors named "Afshin Dowlati"

Are you Afshin Dowlati?   Register this Author

100Publications

2394Reads

41Profile Views

Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer.

Cancer Med 2019 Apr 17;8(4):1459-1466. Epub 2019 Feb 17.

Department of Hematology and Oncology, Case Western Reserve University, University Hospitals Seidman Cancer Center, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488103PMC
April 2019

Diffuse Atypical Cystic Brain Metastases in ALK+ NSCLC Treated With Whole Brain Radiation and Second-Generation ALK-Targeted Therapy.

Pract Radiat Oncol 2019 03 18;9(2):e129-e133. Epub 2019 Jan 18.

University Hospitals Cleveland Medical Center, Cleveland, Ohio.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18798500183032
Publisher Site
http://dx.doi.org/10.1016/j.prro.2018.11.002DOI Listing
March 2019

Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma.

J Clin Pathol 2018 Dec 18;71(12):1108-1115. Epub 2018 Sep 18.

Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2018-205396DOI Listing
December 2018

Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma.

Mol Oncol 2018 12 23;12(12):2124-2135. Epub 2018 Oct 23.

Division of Hematology and Oncology, Case Western Reserve University and University Hospitals Seidman Cancer Center, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/1878-0261.12386DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275277PMC
December 2018

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.

J Clin Oncol 2018 08 15;36(23):2386-2394. Epub 2018 Jun 15.

M. Catherine Pietanza, Lee M. Krug, Mark G. Kris, and Charles M. Rudin, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College; Kaitlin M. Woo, Yevgeniva Bensman, Brenda Hurtado, and Martin Fleisher, Memorial Sloan Kettering Cancer Center, New York, NY; Saiama N. Waqar, Washington University School of Medicine in St. Louis, St Louis, MO; Afshin Dowlati, Case Western Reserve University and University Hospitals Seidman Cancer Center, Cleveland, OH; Christine L. Hann, Johns Hopkins University, Baltimore; Alice Chen, National Institutes of Health, Bethesda, MD; Alberto Chiappori, H. Lee Moffitt Cancer Center, Tampa, FL; Taofeek K. Owonikoko, Emory University, Atlanta, GA; and Robert J. Cardnell, Junya Fujimoto, Lihong Long, Lixia Diao, Jing Wang, Patricia de Groot, Erik P. Sulman, Ignacio I. Wistuba, John V. Heymach, and Lauren Averett Byers, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.77.7672DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085179PMC
August 2018

KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.

Clin Lung Cancer 2018 07 16;19(4):e489-e501. Epub 2018 Mar 16.

Division of Hematology and Oncology, Case Western Reserve University, University Hospitals Seidman Cancer Center, Cleveland, OH. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183004
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.03.005DOI Listing
July 2018

Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.

Rev Recent Clin Trials 2017 ;12(1):51-58

Department of Medicine, University Hospitals Case Medical Center, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574887111666160916130423DOI Listing
June 2018

Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer.

Invest New Drugs 2018 06 2;36(3):435-441. Epub 2017 Oct 2.

Novartis Institute of Biomedical Research, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-017-0515-3DOI Listing
June 2018

A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer.

EBioMedicine 2018 Jun 1;32:102-110. Epub 2018 Jun 1.

National Institute of Occupational Safety and Health, 1095 Willowdale Road, Morgantown, WV 26505, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2018.05.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020749PMC
June 2018

The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing Expression and Targeting Tumor-Initiating Cells.

Cancer Res 2018 05 13;78(9):2396-2406. Epub 2018 Feb 13.

Department of Cancer Biology. Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-17-1920DOI Listing
May 2018

Relationship between phase I study duration and symptom burden.

Support Care Cancer 2018 Mar 5;26(3):731-737. Epub 2017 Oct 5.

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-017-3879-1DOI Listing
March 2018

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

N Engl J Med 2018 02;378(8):731-739

From Memorial Sloan Kettering Cancer Center (A. Drilon, J.F.H., R.B., M.L., D.M.H.) and Weill Cornell Medical College (A. Drilon, D.M.H.), New York; University of Texas Southwestern Medical Center-Children's Health, Dallas (T.W.L.); Stanford Cancer Center, Stanford University, Palo Alto (S.K.), Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California (L.M.), and UCLA David Geffen School of Medicine (N.F.), Los Angeles, and Loxo Oncology, South San Francisco (B.B.T., K.E., S.C., N.C.K., M.C.C.) - all in California; Dana-Farber-Boston Children's Cancer and Blood Disorders Center (S.G.D.), Dana-Farber Cancer Institute (G.D.D., M.N.), Ludwig Center at Harvard (G.D.D.), and Massachusetts General Hospital (A.F.F.) - all in Boston; the Finsen Center, Rigshospitalet, Copenhagen (U.N.L.); University of Colorado, Aurora (R.C.D.); St. Jude Children's Research Hospital, Memphis (A.S.P.), and Vanderbilt University, Nashville (J.B.) - both in Tennessee; Cincinnati Children's Hospital Medical Center, Cincinnati (B.T.); University Hospitals of Cleveland Medical Center (A. Dowlati) and Taussig Cancer Institute, Cleveland Clinic (D.P.S.S.), Cleveland; University of Pennsylvania Perelman School of Medicine, Department of Otorhinolaryngology and Head and Neck Surgery, and the Abramson Cancer Center (M.S.B.), and Fox Chase Cancer Center (W.S.E.-D.), Philadelphia; University of Washington-Seattle Cancer Care Alliance (C.B.), Seattle Children's Hospital (E.R.R.), and Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center (D.S. Hawkins), Seattle; University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B., D.S. Hong); Inova Schar Cancer Institute, Falls Church, VA (J.D.); START Madrid, Centro Integral Oncológico Clara Campal, Madrid (V.B.); Nemours Children's Hospital, Orlando (R.N.), and Memorial Cancer Institute-Florida International University, Miami (L.E.R.) - both in Florida; Oregon Health and Science University, Portland (M.T.); and WVU Cancer Institute, West Virginia University, Morgantown (P.C.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1714448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857389PMC
February 2018

Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer.

Oncotarget 2017 Sep 28;8(43):73745-73756. Epub 2017 Aug 28.

Division of Hematology and Oncology, Case Western Reserve University, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.20572DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650296PMC
September 2017

Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer.

Future Oncol 2017 Jul 7;13(16):1405-1414. Epub 2017 Jul 7.

Department of Radiation Oncology, University Hospitals Seidman Cancer Center, University Hospitals Cleveland Medical Center, 11100 Euclid Ave., Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0045DOI Listing
July 2017

Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.

JAMA Dermatol 2017 05;153(5):413-420

Department of Dermatology, University Hospitals Cleveland Medical Center, Cleveland, Ohio5Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2016.5793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817489PMC
May 2017

Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).

J Thorac Oncol 2017 04 19;12(4):704-713. Epub 2016 Dec 19.

Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; Genomics and Bioinformatics Shared Resource, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Genome Sciences, University of Washington, Seattle, Washington. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.12.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669801PMC
April 2017

Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age >65 years) using national SEER-Medicare data.

Pract Radiat Oncol 2016 Sep-Oct;6(5):e163-e169. Epub 2016 Jan 28.

Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prro.2016.01.011DOI Listing
March 2017

Evaluating the role of phase I expansion cohorts in oncologic drug development.

Invest New Drugs 2017 02 7;35(1):108-114. Epub 2016 Oct 7.

Division of Hematology and Oncology, University Hospitals Cleveland Medical Center/Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0394-zDOI Listing
February 2017

Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.

Cancer Cell 2017 02;31(2):286-299

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.01.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313262PMC
February 2017

RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR.

Oncotarget 2017 Jan;8(4):5992-6002

Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, 44106 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.13362DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351607PMC
January 2017

Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine.

Radiother Oncol 2016 11 9;121(2):335-341. Epub 2016 Nov 9.

Department of Radiation Oncology, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, USA; Case Comprehensive Cancer Center, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2016.10.007DOI Listing
November 2016

Genomic alterations in small cell lung cancer and their clinical relevance.

Transl Lung Cancer Res 2016 Aug;5(4):450-1

Department of Hematology & Oncology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2016.07.05DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009082PMC
August 2016

Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologies.

Am Soc Clin Oncol Educ Book 2015 :147-62

From The University of Texas Southwestern Medical Center, Dallas, TX; Memorial Sloan Kettering Cancer Center, New York, NY; Case Western Reserve University, Cleveland, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.147DOI Listing
February 2016

Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancer.

PLoS One 2014 8;9(9):e106784. Epub 2014 Sep 8.

Case Comprehensive Cancer Center and the Division of Hematology and Oncology, Case Western Reserve University, Cleveland, Ohio, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0106784PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157793PMC
May 2015

PIAS3 expression in squamous cell lung cancer is low and predicts overall survival.

Cancer Med 2015 Mar 9;4(3):325-32. Epub 2015 Jan 9.

Division of Pulmonary and Critical Care Medicine, University Hospitals Medical Center, Case Western Reserve University, Cleveland, Ohio, 44106.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.372DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380958PMC
March 2015

CD30 is a potential therapeutic target in malignant mesothelioma.

Mol Cancer Ther 2015 Mar 14;14(3):740-6. Epub 2015 Jan 14.

Division of Hematology and Oncology, Case Comprehensive Cancer Center and University Hospitals Case Medical Center, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-14-0972DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456236PMC
March 2015

Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survival.

Clin Cancer Res 2014 Oct 14;20(19):5124-32. Epub 2014 Aug 14.

Division of Hematology and Oncology, Case Comprehensive Cancer Center and University Hospitals Case Medical Center, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1233DOI Listing
October 2014

RET mutation and expression in small-cell lung cancer.

J Thorac Oncol 2014 Sep;9(9):1316-23

*Division of Hematology and Oncology, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio; †Department of Medicine, MedStar Good Samaritan Hospital, Baltimore, Maryland; ‡Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio; §Division of Pathology, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio; and ‖Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000234DOI Listing
September 2014

Defining subgroups of small-cell lung cancer.

J Thorac Oncol 2014 Jun;9(6):750-1

Division of Hematology and Oncology, Case Western Reserve University and University Hospitals Seidman Cancer Center and the Case Comprehensive Cancer Center, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000176DOI Listing
June 2014

Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution.

Clin Lung Cancer 2014 May 27;15(3):207-12. Epub 2013 Dec 27.

Division of Hematology and Oncology, Department of Biostatistics and Epidemiology, Case Western Reserve University and University Hospitals Seidman Cancer Center and Case Comprehensive Cancer Center. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2013.12.001DOI Listing
May 2014

Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.

Invest New Drugs 2014 Apr 15;32(2):362-8. Epub 2014 Jan 15.

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-0061-6DOI Listing
April 2014

PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status.

Int J Cancer 2014 Mar 23;134(5):1045-54. Epub 2013 Sep 23.

Division of Hematology and Oncology, Case Western Reserve University, Cleveland, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.28448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199747PMC
March 2014

The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations.

J Oncol Pract 2013 Nov 15;9(6):267-76. Epub 2013 Oct 15.

National Cancer Institute; Education Network to Advance Cancer Clinical Trials, Bethesda; The EMMES Corporation, Rockville, MD; Delaware Cancer Consortium, Dover; Helen F. Graham Cancer Center, Newark, DE; American Society of Clinical Oncology, Alexandria, VA; Coalition of Cancer Cooperative Groups; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Cancer Information & Support Network, Auburn, CA; Oregon Health & Science University, Portland, OR; Pancreatic Cancer Action Network; Brooklyn Hospital Center, New York, NY; Massachusetts General Hospital, Boston, MA; Duke Clinical Research Institute, Durham; Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; Michiana Hematology Oncology and Northern Indiana Cancer Research Consortium, South Bend, IN; Barbara Ann Karmanos Cancer Institute, Detroit, MI; University of Arizona Cancer Center, Tucson, AZ; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland; The Ohio State University, Columbus, OH; University of Alabama at Birmingham, Birmingham, AL; Indiana University Simon Cancer Center, Indianapolis, IN; Heartland Cancer Research CCOP, St. Louis, MO; Meharry Medical College; and Vanderbilt-Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2013.001119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825288PMC
November 2013

A Phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer.

Invest New Drugs 2013 Oct 4;31(5):1244-50. Epub 2013 Apr 4.

University Hospitals, Seidman Cancer Center, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, OH, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-9945-8DOI Listing
October 2013

Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.

Gynecol Oncol 2013 Jul 18;130(1):75-80. Epub 2013 Apr 18.

Department of Radiation Oncology, CASE Comprehensive Cancer Center, University Hospitals Case Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2013.04.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260802PMC
July 2013

Synthesis and anticancer mechanism investigation of dual Hsp27 and tubulin inhibitors.

J Med Chem 2013 Jul 28;56(13):5306-20. Epub 2013 Jun 28.

Department of Chemistry, College of Sciences and Health Professions, Cleveland State University , 2121 Euclid Avenue, Cleveland, Ohio 44115, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm4004736DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855081PMC
July 2013

Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.

Thyroid 2013 May 18;23(5):600-4. Epub 2013 Apr 18.

Division of Hematology/Oncology, Seidman Cancer Center, University Hospitals , Cleveland, OH 44106, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2012.0103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643255PMC
May 2013

Combined SCLC clinical and pathologic characteristics.

Clin Lung Cancer 2013 Mar 24;14(2):113-9. Epub 2012 Sep 24.

Division of Hematology and Oncology, Case Western Reserve University, University Hospital Case Medical Center, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2012.07.002DOI Listing
March 2013

Phase I trials of targeted anticancer drugs: a need to refocus.

Nat Rev Drug Discov 2012 Dec;11(12):889-90

Case Comprehensive Cancer Center, Taussig Cancer Institute R40, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd3909DOI Listing
December 2012

Phase I trial of pomalidomide given for patients with advanced solid tumors.

Cancer Chemother Pharmacol 2012 Nov 9;70(5):755-61. Epub 2012 Aug 9.

Division of Hematology and Oncology, University Hospitals Case Medical Center, Case Comprehensive Cancer Center, 11100 Euclid Avenue, Cleveland, OH 44106, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-012-1919-6DOI Listing
November 2012

Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.

J Clin Oncol 2012 Aug 9;30(23):2919-28. Epub 2012 Jul 9.

Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2011.39.7356
Publisher Site
http://dx.doi.org/10.1200/JCO.2011.39.7356DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3410405PMC
August 2012

Five-year survival does not equal cure in non-small cell lung cancer: a Surveillance, Epidemiology, and End Results-based analysis of variables affecting 10- to 18-year survival.

J Thorac Cardiovasc Surg 2012 Jun 22;143(6):1307-13. Epub 2012 Feb 22.

Case Western Reserve School of Medicine, University Hospitals-Case Medical Center, Cleveland, Ohio 44124, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtcvs.2012.01.078DOI Listing
June 2012

Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.

J Thorac Oncol 2012 May;7(5):856-65

Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31824c943fDOI Listing
May 2012

Identification of a class of novel tubulin inhibitors.

J Med Chem 2012 Apr 2;55(7):3425-35. Epub 2012 Apr 2.

Department of Chemistry, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Avenue, Cleveland, Ohio 44115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm300100dDOI Listing
April 2012

From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation.

Eur J Med Chem 2012 Jan 15;47(1):432-444. Epub 2011 Nov 15.

Department of Chemistry, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, OH, 44115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2011.11.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166484PMC
January 2012

Identification of STAT3-independent regulatory effects for protein inhibitor of activated STAT3 by binding to novel transcription factors.

Cancer Biol Ther 2011 Jul 15;12(2):139-51. Epub 2011 Jul 15.

Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154286PMC
http://dx.doi.org/10.4161/cbt.12.2.15732DOI Listing
July 2011

Protein inhibitor of activated STAT3 expression in lung cancer.

Mol Oncol 2011 Jun 30;5(3):256-64. Epub 2011 Mar 30.

Division of Hematology/Oncology, Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, Ohio, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2011.03.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104085PMC
June 2011

Temporal evolution of patient characteristics enrolled on phase I trials.

Invest New Drugs 2011 Apr 9;29(2):312-5. Epub 2009 Dec 9.

Division of Hematology/Oncology, Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-009-9362-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199750PMC
April 2011

Phase I Clinical Trials in Patients ≥80.

J Geriatr Oncol 2011 Apr;2(2):142-146

Division of Hematology/Oncology, Case Western Reserve University and University Hospitals Case Medical Center and the Developmental Therapeutics Program, Case Comprehensive Cancer Center, Cleveland, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2011.01.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3097467PMC
April 2011

Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.

Clin Cancer Res 2010 Feb 9;16(4):1298-306. Epub 2010 Feb 9.

Department of Radiation Oncology, Case Comprehensive Cancer Center, University Hospitals Case Medical Center and Case Western Reserve School of Medicine, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-2469DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822897PMC
February 2010

Hunting and trapping the vascular endothelial growth factor.

Authors:
Afshin Dowlati

J Clin Oncol 2010 Jan 30;28(2):185-7. Epub 2009 Nov 30.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.25.4359DOI Listing
January 2010

Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers.

Cancer Chemother Pharmacol 2009 Dec 28;65(1):73-8. Epub 2009 Apr 28.

University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-009-1005-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220168PMC
December 2009

The association and nuclear translocation of the PIAS3-STAT3 complex is ligand and time dependent.

Mol Cancer Res 2009 Nov 10;7(11):1854-60. Epub 2009 Nov 10.

Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-09-0313DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783234PMC
November 2009

Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer.

Int J Cancer 2009 Oct;125(7):1728-34

Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.24553DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764252PMC
October 2009

Comparison of power between randomized discontinuation design and upfront randomization design on progression-free survival.

J Clin Oncol 2009 Sep 27;27(25):4135-41. Epub 2009 Jul 27.

Department of Epidemiology and Biostatistics, Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.19.6709DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2734425PMC
September 2009

Controversies in multi-institutional phase I clinical trials.

Authors:
Afshin Dowlati

Clin Adv Hematol Oncol 2009 Aug;7(8):518-20

Case Western Reserve University Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
August 2009

Phase I trial of pazopanib in patients with advanced cancer.

Clin Cancer Res 2009 Jun 9;15(12):4220-7. Epub 2009 Jun 9.

Duke University Medical Center, Durham, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-2740DOI Listing
June 2009